Special Issue "Human Hepatocellular Carcinoma (HCC)"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 March 2020).
Interests: cancer immunotherapy; cancer vaccines; hepatocellular carcinoma; tumor microenvironment
Special Issues and Collections in MDPI journals
Every year, more than 800 thousands people die from human hepatocellular carcinoma (HCC) worldwide, making it the sixth most common cancer and the third leading cause of cancer death. Surgical, loco-regional, and systemic therapies for HCC are dependent on the stage of disease, but the clinical outcome is poor.
In such an adverse scenario, immunotherapeutic approaches may represent a valuable tool. In particular, combination strategies should be designed to elicit anti-tumoral immunity and counteract the immunosuppressive microenvironment. However, results remain unsatisfactory, and improvements are needed in order to define the optimal target antigens, delivery strategies, and therapeutic combination. This Special Issue will address the ultimate frontier of therapy in HCC.
Dr. Luigi Buonaguro
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- human hepatocellular carcinoma (HCC)
- cancer vaccine
- combination strategies